---
id: new-limit-epigenetic
slug: new-limit-epigenetic
entity_type: commercial
status: operational
data_completeness: high
last_researched: 2025-12-23
researcher: AI Assistant
version: 2.1
name: NewLimit - Single-cell ML for Epigenetic Reprogramming
description: Biotechnology company developing epigenetic reprogramming therapies using machine learning on single-cell multimodal data to restore youthful function in aged cells
mission: To extend human healthspan by developing epigenetic reprogramming therapies that restore youthful function to aged cells without altering their identity. The company aims to overcome traditional barriers in epigenetic reprogramming by combining advances in single-cell genomics, epigenetic editing, and machine learning to create safe and effective rejuvenation therapies.
entity_data:
  name: NewLimit
  focus: Development of epigenetic reprogramming therapies to restore youthful function in aged cells and extend human healthspan
  status: operational
  founded: 2021
  website: "https://www.newlimit.com"
  industry: Biotechnology
  employees:
  legal_name: NewLimit, Inc.
  headquarters:
  city: South San Francisco
  state: California
  address: South San Francisco, California
  country: USA
taxonomy:
  geography: USA
  ai_technology:
  - Predictive ML/DL
  primary_focus:
  - Cellular Rejuvenation
  aging_approach:
  - Cellular Rejuvenation
  - Therapeutic Development
  target_biology:
  - Neurodegenerative
  - Fibrosis
  - General Aging/Longevity
  development_stage: Research / Preclinical
  organization_type: commercial
  organization_subtype: operational
  therapeutic_modality:
  - Gene Therapy
organizations:
  -
    name: Founders Fund
    role: partner
    org_type: company
    status: operational
    role_description: Investor in Series A ($40M) and Series B ($130M) rounds
  -
    name: S32
    role: partner
    org_type: company
    status: operational
    role_description: Strategic investor in $45M strategic investment round
  -
    name: NewLimit
    role: primary
    org_type: company
    legal_name: NewLimit, Inc.
    founded: 2021
    website: "https://www.newlimit.com"
    status: operational
    role_description: "Primary organization: Biotechnology company developing epigenetic reprogramming therapies"
  -
    name: Eli Lilly
    role: partner
    org_type: company
    website: "https://www.lilly.com/"
    status: operational
    role_description: Strategic investor in $45 million strategic investment round
  -
    name: Kleiner Perkins
    role: partner
    org_type: company
    status: operational
    role_description: Lead investor in Series B round ($130M), also participated in Series A ($40M)
  -
    name: Khosla Ventures
    role: partner
    org_type: company
    status: operational
    role_description: Investor in Series B round ($130M)
  -
    name: Dimension
    role: partner
    org_type: company
    status: operational
    role_description: Investor in Series A ($40M) and Series B ($130M) rounds
  -
    name: Duke University
    role: partner
    org_type: institution
    legal_name: Duke University
    website: "https://www.duke.edu/"
    status: operational
    role_description: Strategic investor and research collaborator in $45 million strategic investment round
products:
  -
    name: Epigenetic Reprogramming Platform
    type: platform
    status: Preclinical development
    development_stage: preclinical
links:
  -
    url: "https://www.nature.com/articles/s41587-021-00895-7"
    type: research_publication
    title: Single-cell multimodal data integration in biology
  -
    url: "https://www.crunchbase.com/organization/newlimit"
    type: reference
    title: NewLimit - Crunchbase Company Profile & Funding
  -
    url: "https://longevity.technology/news/lilly-invests-in-epigenetic-reprogramming-biotech/"
    type: news_article
    title: Lilly invests in epigenetic reprogramming biotech
  -
    url: "https://blog.newlimit.com/p/may-june-2025-progress-update"
    type: blog_post
    title: May // June 2025 – Progress Update
  -
    url: "https://techcrunch.com/2025/05/06/newlimit-founded-by-coinbase-ceo-brian-armstrong-raises-130m-to-develop-age-reversing-therapies/"
    type: news_article
    title: NewLimit, founded by Coinbase CEO Brian Armstrong, raises $130M to develop age-reversing treatments
  -
    url: "https://www.newlimit.com/operating-plan"
    type: documentation
    title: NewLimit Operating Plan
  -
    url: "https://www.drivingeco.com/ru/Newlimit-%D0%BF%D1%80%D0%B8%D0%B2%D0%BB%D0%B5%D0%BA%D0%B0%D1%82-130-%D0%BC%D0%B8%D0%BB%D0%BB%D0%B8%D0%BE%D0%BD%D0%BE%D0%B2-%D0%B4%D0%BE%D0%BB%D0%BB%D0%B0%D1%80%D0%BE%D0%B2-%D0%BD%D0%B0-%D0%BE%D0%BC%D0%BE%D0%BB%D0%BE%D0%B6%D0%B5%D0%BD%D0%B8%D0%B5-%D1%87%D0%B5%D0%BB%D0%BE%D0%B2%D0%B5%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D1%85-%D0%BA%D0%BB%D0%B5%D1%82%D0%BE%D0%BA/"
    type: news_article
    title: NewLimit привлекает 130 миллионов долларов на омоложение человеческих клеток с помощью биотехнологий
  -
    url: "https://longevity.openclinics.ru/blog/life-biosciences/"
    type: reference
    title: Life Biosciences - Epigenetic reprogramming for longevity
  -
    url: "https://planet-today.ru/novosti/nauka/item/160425-novoe-issledovanie-svyazyvaet-epigeneticheskoe-starenie-s-kognitivnym-funktsionirovaniem"
    type: news_article
    title: Epigenetic aging and cognitive function
  -
    url: "https://blog.newlimit.com/p/january-february-2024-progress-update"
    type: blog_post
    title: January // February 2024 Progress Update
  -
    url: "https://www.newlimit.com/science"
    type: website
    title: NewLimit Science
  -
    url: "https://www.nature.com/articles/s41587-022-01434-8"
    type: research_publication
    title: Partial reprogramming for cellular rejuvenation
  -
    url: "https://blog.newlimit.com/p/may-june-2024-update"
    type: blog_post
    title: May // June 2024 Update
  -
    url: "https://phemex.com/ru/news/article/newlimit-raises-45-million-to-advance-longevity-research-28470"
    type: news_article
    title: NewLimit raises $45 million to advance longevity research
---

# NewLimit - Single-cell ML for Epigenetic Reprogramming

## Description

Biotechnology company developing epigenetic reprogramming therapies using machine learning on single-cell multimodal data to restore youthful function in aged cells

## Mission

To extend human healthspan by developing epigenetic reprogramming therapies that restore youthful function to aged cells without altering their identity. The company aims to overcome traditional barriers in epigenetic reprogramming by combining advances in single-cell genomics, epigenetic editing, and machine learning to create safe and effective rejuvenation therapies.

## Company Information

**Legal Name**: NewLimit, Inc.
**Founded**: 2021
**Industry**: Biotechnology
**Employees**: {"as_of":null,"current":null}
**Focus**: Development of epigenetic reprogramming therapies to restore youthful function in aged cells and extend human healthspan
**Website**: https://www.newlimit.com

## Scientific Background

```yaml
t_cell_focus: Initial focus on T-cell reprogramming because T-cells are critical for immune function and show clear age-related decline. The platform helps identify safe reprogramming protocols that restore T-cell function without causing harmful side effects.
oskm_and_beyond: "Traditional reprogramming uses OSKM factors (Oct4, Sox2, Klf4, c-Myc). NewLimit's ML platform explores beyond OSKM to identify optimal factor combinations for safe partial reprogramming that restores youth without causing dedifferentiation or cancer risk."
historical_context:
  ml_advancement: Recent advances in single-cell genomics and machine learning have enabled more precise control of reprogramming, allowing identification of factor combinations that achieve rejuvenation while maintaining cellular identity
  safety_challenges: Early partial reprogramming attempts faced challenges including incomplete rejuvenation, variable outcomes across cell types, and safety concerns about dedifferentiation and cancer risk
  yamanaka_factors_discovery: In 2006, Shinya Yamanaka discovered that four transcription factors (OSKM) could reprogram somatic cells into induced pluripotent stem cells (iPSCs), revolutionizing regenerative medicine
  partial_reprogramming_evolution: Subsequent research showed that transient expression of reprogramming factors (partial reprogramming) could rejuvenate cells without full dedifferentiation, opening the door to in vivo applications
safety_considerations:
  cancer_risk: Reprogramming factors (especially c-Myc) are oncogenes, raising concerns about cancer risk if not carefully controlled
  teratoma_formation: Incomplete reprogramming or leakage of reprogramming factors could lead to teratoma formation in vivo
  dedifferentiation_risk: Full reprogramming can cause cells to lose their specialized identity, which is undesirable for in vivo applications
  newlimit_safety_approach: ML models identify epigenetic signatures that distinguish safe rejuvenation from dangerous dedifferentiation, enabling design of safer protocols
single_cell_ml_approach: NewLimit uses machine learning on single-cell multimodal data (combining chromatin accessibility and transcriptome data) to identify patterns that correlate with successful rejuvenation. The AI models can predict outcomes of different reprogramming factor combinations, guiding experimental design and reducing the need for exhaustive screening.
biological_justification:
  reversibility: Epigenetic changes are reversible, unlike genetic mutations, making epigenetic reprogramming a promising approach for age reversal
  epigenetic_aging: Aging is associated with progressive changes in epigenetic marks (DNA methylation, histone modifications) that alter gene expression patterns, contributing to functional decline
  cellular_identity: Partial reprogramming can restore youthful epigenetic patterns while maintaining cell type-specific gene expression programs, preserving cellular identity
  functional_restoration: By restoring youthful epigenetic states, cells regain functional capabilities (regeneration, stress resistance, metabolic efficiency) that decline with age
comparison_to_existing_methods:
  oskm_limitations: Standard OSKM approaches have low efficiency, variable outcomes, and safety concerns (dedifferentiation, cancer risk), limiting clinical applicability
  newlimit_advantages: ML-guided approach identifies optimal factor combinations beyond OSKM, achieving higher success rates, better safety profiles, and more targeted functional restoration
  predictive_capability: In silico prediction reduces experimental burden and enables systematic exploration of factor space, unlike trial-and-error approaches
  single_cell_advantage: Single-cell resolution enables identification of heterogeneous responses and optimization for specific cell types, unlike bulk approaches
epigenetic_reprogramming_mechanism: Epigenetic reprogramming involves modifying the epigenome (chemical modifications to DNA and histones that control gene expression) to restore youthful function in aged cells without altering their identity. This differs from full reprogramming (which creates pluripotent stem cells) by using partial reprogramming approaches.
```

## Lessons Learned

### Achievements

- Successfully developed ML platform that can predict reprogramming outcomes
- Completed preclinical studies showing restoration of youthful functions in aged hepatocytes
- Raised significant funding ($325M total) demonstrating investor confidence
- Attracted strategic investors (Eli Lilly, Duke University) indicating validation of approach
- Built strong scientific advisory board with leading experts in relevant fields

### Challenges

- Epigenetic state space is vast and complex, requiring sophisticated ML approaches to identify successful reprogramming patterns
- Balancing rejuvenation benefits with safety concerns (avoiding dedifferentiation and cancer risk)
- Optimizing experimental design to reduce cost and time of exhaustive screening
- Translating in silico predictions to successful in vivo outcomes

### Impact on Field

NewLimit represents a significant advancement in applying machine learning to epigenetic reprogramming. By using single-cell multimodal data and predictive modeling, the company is making safe partial reprogramming optimization feasible. This approach could enable in vivo partial reprogramming by predicting how to achieve rejuvenation without teratoma formation, which would be a cornerstone of defeating aging. The company's focus on T-cells, liver, and vascular systems addresses critical age-related health issues.

## Organizations

### Founders Fund
**Role in Project**: partner
**Role Description**: Investor in Series A ($40M) and Series B ($130M) rounds
**Organization Type**: company
**Status**: operational
**Description**: Venture capital firm, investor in Series A and Series B rounds
**Focus**: Venture capital investments

### S32
**Role in Project**: partner
**Role Description**: Strategic investor in $45M strategic investment round
**Organization Type**: company
**Status**: operational
**Description**: Venture capital firm, strategic investor
**Focus**: Venture capital investments

### NewLimit
**Legal Name**: NewLimit, Inc.
**Role in Project**: primary
**Role Description**: Primary organization: Biotechnology company developing epigenetic reprogramming therapies
**Organization Type**: company
**Status**: operational
**Founded**: 2021
**Website**: https://www.newlimit.com
**Description**: Biotechnology company developing epigenetic reprogramming therapies to restore youthful function in aged cells and extend human healthspan
**Focus**: Development of epigenetic reprogramming therapies to restore youthful function in aged cells and extend human healthspan

### Eli Lilly
**Role in Project**: partner
**Role Description**: Strategic investor in $45 million strategic investment round
**Organization Type**: company
**Status**: operational
**Website**: https://www.lilly.com/
**Description**: Global pharmaceutical company
**Focus**: Pharmaceutical research and development

### Kleiner Perkins
**Role in Project**: partner
**Role Description**: Lead investor in Series B round ($130M), also participated in Series A ($40M)
**Organization Type**: company
**Status**: operational
**Description**: Venture capital firm, lead investor in Series B round
**Focus**: Venture capital investments

### Khosla Ventures
**Role in Project**: partner
**Role Description**: Investor in Series B round ($130M)
**Organization Type**: company
**Status**: operational
**Description**: Venture capital firm, investor in Series B round
**Focus**: Venture capital investments

### Dimension
**Role in Project**: partner
**Role Description**: Investor in Series A ($40M) and Series B ($130M) rounds
**Organization Type**: company
**Status**: operational
**Description**: Venture capital firm, investor in Series A and Series B rounds
**Focus**: Venture capital investments

### Duke University
**Role in Project**: partner
**Role Description**: Strategic investor and research collaborator in $45 million strategic investment round
**Organization Type**: institution
**Status**: operational
**Website**: https://www.duke.edu/
**Description**: Private research university in Durham, North Carolina. Primary research institution for DunedinPACNI development.
**Focus**: Department of Psychology and Neuroscience, Moffitt-Caspi Lab, neuroimaging research, brain aging model development

## Locations

### Durham, USA
**Type**: institution
**City**: Durham
**State/Region**: North Carolina
**Country**: USA
**Organizations**: Duke University

### NewLimit Headquarters
**Type**: headquarters
**Address**: South San Francisco, California
**City**: South San Francisco
**State/Region**: California
**Country**: USA
**Organizations**: NewLimit

## Products

### Epigenetic Reprogramming Platform
**Alternative Names**: Single-cell ML Platform for Epigenetic Reprogramming
**Type**: platform
**Status**: Preclinical development
**Development Stage**: preclinical
**Role in Project**: primary
**Relationship Description**: Primary platform: ML-guided epigenetic reprogramming platform
**Description**: Machine learning platform for optimizing epigenetic reprogramming therapies. Uses single-cell multimodal data to identify key epigenetic marks and gene expression changes that signify successful cellular rejuvenation without becoming cancerous.
**Mechanism of Action**: Uses machine learning on single-cell multimodal data (chromatin accessibility, transcriptome) to identify key epigenetic marks and gene expression changes that signify successful cellular rejuvenation without becoming cancerous. The platform predicts outcomes of different reprogramming factor combinations or time courses to optimize experimental design.
**Target**: Epigenetic state of aged cells
**Pathway**: Epigenetic reprogramming pathways (OSKM and beyond)
**Indications**: [
  {
    "primary": "T-cell rejuvenation",
    "description": "Restoring youthful function in aged T-cells to improve immune response in older individuals"
  },
  {
    "primary": "Liver disease",
    "description": "Restoring youthful function in aging hepatocytes to treat liver diseases"
  },
  {
    "primary": "Vascular system aging",
    "description": "Restoring function in endothelial cells to address age-related vascular diseases"
  }
]
**Clinical Trials**:
```yaml
-
  name: Humanized Liver Model Studies
  model: Humanized liver models
  phase: Preclinical
  status: Completed
  results:
  summary: Completed first studies in humanized liver models. Several transcription factor sets restored various youthful functions in aged hepatocytes. One leading candidate restored liver regenerative capacity after injury, while two other sets enhanced resistance to injury, achieving near-youthful levels of protection from toxins such as alcohol.
  toxin_protection: Achieved near-youthful levels of protection from toxins such as alcohol
  quantitative_metrics:
  safety_metrics: No evidence of dedifferentiation or cancer risk in successfully reprogrammed cells, maintaining hepatocyte identity
  functional_restoration: "Multiple youthful functions were restored across different transcription factor combinations, demonstrating the platform's ability to identify diverse successful reprogramming strategies"
  injury_resistance_level: Two transcription factor sets enhanced resistance to injury, achieving protection levels approaching those of youthful hepatocytes
  alcohol_toxin_protection: Near-youthful levels of protection from alcohol and other toxins were achieved, indicating restoration of detoxification capacity
  regenerative_capacity_improvement: One transcription factor set restored regenerative capacity in aged hepatocytes, enabling recovery after injury comparable to young cells
  resistance_to_injury: Enhanced to near-youthful levels in two other candidates
  regenerative_capacity: Restored in one leading candidate
  comparison_to_baseline:
  baseline: Standard OSKM (Oct4, Sox2, Klf4, c-Myc) reprogramming approaches
  advantage: "NewLimit's ML-guided approach identified factor combinations beyond OSKM that achieve partial reprogramming with better safety profiles and more targeted functional restoration"
  efficiency: ML platform reduced experimental screening burden by prioritizing factor combinations, enabling faster identification of successful candidates
  indication: Liver rejuvenation
  start_date: 2024
  publications: []
  completion_date: Late 2024
```
**Technical Details**:
```yaml
notes: Platform is being used to optimize experimental design for safe partial reprogramming. Instead of blindly trying dozens of factor cocktails, researchers use AI suggestions to focus on combinations likely to work safely, particularly for T-cells which are the initial focus.
methodology:
  overview: "NewLimit's approach combines single-cell genomics, machine learning, and high-throughput functional assays to identify and validate safe epigenetic reprogramming interventions"
  step_by_step_process:
  -
  step: 1
  description: "Single-cell profiling: Collect chromatin accessibility (ATAC-seq) and transcriptome (RNA-seq) data from individual cells at different stages of aging and reprogramming"
  -
  step: 2
  description: "Data integration: Integrate multimodal single-cell data to create unified representations of cellular epigenetic and transcriptional states"
  -
  step: 3
  description: "Pattern identification: Use ML models to identify epigenetic marks and gene expression patterns that correlate with successful rejuvenation without dedifferentiation"
  -
  step: 4
  description: "Factor prediction: Predict which transcription factor combinations and time courses are most likely to achieve safe partial reprogramming"
  -
  step: 5
  description: "Experimental prioritization: Rank predicted factor combinations by success probability and safety, focusing experimental efforts on highest-priority candidates"
  -
  step: 6
  description: "Functional validation: Test prioritized factor combinations in high-throughput functional assays (e.g., humanized liver models, T-cell function assays)"
  -
  step: 7
  description: "Iterative refinement: Feed experimental results back into ML models to improve predictions for subsequent rounds of optimization"
  validation_procedures:
  safety_validation: Cells are monitored for dedifferentiation markers, cancer risk indicators, and maintenance of cellular identity
  in_silico_validation: ML model predictions are validated against known experimental outcomes to assess prediction accuracy
  functional_validation: Restored youthful functions are measured quantitatively (e.g., regenerative capacity, resistance to injury, functional assays)
  experimental_validation: Predicted factor combinations are tested in functional assays (liver regeneration, T-cell function, etc.)
  single_cell_data_processing:
  multimodal_integration: Combining both data types at single-cell resolution enables identification of coordinated epigenetic and transcriptional changes
  transcriptome_analysis: RNA-seq measures gene expression levels, providing information about cellular function and identity
  chromatin_accessibility: ATAC-seq (Assay for Transposase-Accessible Chromatin with sequencing) measures open chromatin regions, indicating active regulatory elements
  cell_state_characterization: Single-cell resolution allows identification of heterogeneous cell populations and tracking of individual cell trajectories during reprogramming
ml_approach: Machine learning models analyze single-cell multimodal data combining chromatin accessibility (ATAC-seq) and transcriptome (RNA-seq) measurements to identify epigenetic patterns associated with successful rejuvenation
model_training: Models are trained on experimental data where reprogramming outcomes (successful rejuvenation vs. dedifferentiation/cancer) are known, enabling supervised learning
data_integration: Multimodal integration of chromatin accessibility and gene expression data at single-cell resolution allows identification of coordinated changes in epigenetic state and transcriptional output
data_requirements: Requires large-scale single-cell datasets from both young and aged cells, as well as cells undergoing various reprogramming protocols to train predictive models
safety_prediction: AI models identify epigenetic signatures that distinguish successful rejuvenation from dedifferentiation or cancer risk, enabling safer experimental design
validation_approach: Predictions are validated through experimental testing, with results fed back into model training for iterative improvement
prediction_capability: Models predict outcomes of different reprogramming factor combinations and time courses, enabling in silico screening before experimental validation
experimental_optimization: Platform reduces experimental screening burden by prioritizing factor combinations with highest predicted success probability and lowest predicted safety risk
```

## Key People

### Mark Davis
**Title**: Scientific Advisor
**Participation Type**: advisor
**Role in Project**: Scientific Advisor
**Expertise**: T cell biology, immunology
**Biography**: Renowned immunologist known for his work on T cell biology

### Alex Marson
**Title**: Scientific Advisor
**Participation Type**: advisor
**Role in Project**: Scientific Advisor
**Expertise**: Gene regulation, immune cell engineering
**Biography**: Geneticist specializing in gene regulation and immune cell engineering

### Ron Hause
**Title**: Head of Computational Sciences
**Participation Type**: leadership
**Role in Project**: Head of Computational Sciences
**Expertise**: Computational biology, predictive modeling, AI
**Biography**: Previously served as SVP and Head of AI at Shape Therapeutics. Leads Computational Biology and Predictive Modeling efforts at NewLimit

### Markus Grompe
**Title**: Scientific Advisor
**Participation Type**: advisor
**Role in Project**: Scientific Advisor
**Expertise**: Liver regeneration, stem cell biology
**Biography**: Stem cell biologist with significant contributions to liver regeneration research

### E. John Wherry
**Title**: Scientific Advisor
**Participation Type**: advisor
**Role in Project**: Scientific Advisor
**Expertise**: T cell exhaustion, immunotherapy
**Biography**: Expert in T cell exhaustion and immunotherapy

### Brian Armstrong
**Title**: Co-founder
**Participation Type**: founder
**Role in Project**: Co-founder
**Expertise**: Technology entrepreneurship, software engineering
**Biography**: CEO and co-founder of Coinbase, a leading cryptocurrency exchange platform. Previously worked as a software engineer at Airbnb and IBM.

### Blake Byers
**Title**: Co-founder
**Participation Type**: founder
**Role in Project**: Co-founder
**Expertise**: Biotechnology investments, venture capital
**Biography**: Former partner at GV (formerly Google Ventures) with extensive background in biotechnology investments and venture capital

### Hao Zhu
**Title**: Scientific Advisor
**Participation Type**: advisor
**Role in Project**: Scientific Advisor
**Expertise**: Liver regeneration, cancer biology
**Biography**: Researcher focusing on liver regeneration and cancer biology

### Jacob Kimmel
**Title**: Co-founder, Chief Scientific Officer
**Participation Type**: founder
**Role in Project**: Co-founder, Chief Scientific Officer
**Expertise**: Cellular reprogramming, stem cell biology, aging research
**Biography**: Stem cell researcher with expertise in cellular reprogramming and aging research

## Links

### [Single-cell multimodal data integration in biology](https://www.nature.com/articles/s41587-021-00895-7)
**Type**: research_publication
**Relevance**: secondary
**Category**: reference
**Relationship Description**: Scientific publication on single-cell multimodal data integration (context)
**Publisher**: Nature Biotechnology
**Description**: Review on methods for integrating single-cell multimodal data (technical context for NewLimit's approach)

### [NewLimit - Crunchbase Company Profile & Funding](https://www.crunchbase.com/organization/newlimit)
**Type**: reference
**Relevance**: secondary
**Category**: reference
**Relationship Description**: Crunchbase profile with funding and company information
**Publisher**: Crunchbase
**Description**: Crunchbase profile with funding and company information

### [Lilly invests in epigenetic reprogramming biotech](https://longevity.technology/news/lilly-invests-in-epigenetic-reprogramming-biotech/)
**Type**: news_article
**Relevance**: primary
**Category**: publication
**Relationship Description**: News coverage of Eli Lilly strategic investment
**Publisher**: Longevity Technology
**Publication Date**: 2025-10-01
**Description**: News about Eli Lilly strategic investment

### [May // June 2025 – Progress Update](https://blog.newlimit.com/p/may-june-2025-progress-update)
**Type**: blog_post
**Relevance**: primary
**Category**: source
**Relationship Description**: Company progress update blog post (June 2025)
**Publisher**: NewLimit
**Publication Date**: 2025-06-01
**Description**: Progress update on company developments and research milestones

### [NewLimit, founded by Coinbase CEO Brian Armstrong, raises $130M to develop age-reversing treatments](https://techcrunch.com/2025/05/06/newlimit-founded-by-coinbase-ceo-brian-armstrong-raises-130m-to-develop-age-reversing-therapies/)
**Type**: news_article
**Relevance**: primary
**Category**: publication
**Relationship Description**: TechCrunch coverage of Series B funding round
**Publisher**: TechCrunch
**Publication Date**: 2025-05-06
**Description**: TechCrunch article about Series B funding round

### [NewLimit Operating Plan](https://www.newlimit.com/operating-plan)
**Type**: documentation
**Relevance**: primary
**Category**: source
**Relationship Description**: Company operating plan and strategic approach
**Publisher**: NewLimit
**Description**: Company's operating plan and strategic approach

### [NewLimit привлекает 130 миллионов долларов на омоложение человеческих клеток с помощью биотехнологий](https://www.drivingeco.com/ru/Newlimit-%D0%BF%D1%80%D0%B8%D0%B2%D0%BB%D0%B5%D0%BA%D0%B0%D1%82-130-%D0%BC%D0%B8%D0%BB%D0%BB%D0%B8%D0%BE%D0%BD%D0%BE%D0%B2-%D0%B4%D0%BE%D0%BB%D0%BB%D0%B0%D1%80%D0%BE%D0%B2-%D0%BD%D0%B0-%D0%BE%D0%BC%D0%BE%D0%BB%D0%BE%D0%B6%D0%B5%D0%BD%D0%B8%D0%B5-%D1%87%D0%B5%D0%BB%D0%BE%D0%B2%D0%B5%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D1%85-%D0%BA%D0%BB%D0%B5%D1%82%D0%BE%D0%BA/)
**Type**: news_article
**Relevance**: secondary
**Category**: publication
**Relationship Description**: Russian news coverage of Series B funding
**Publisher**: DrivingEco
**Publication Date**: 2025-05-01
**Description**: Russian news article about Series B funding

### [Life Biosciences - Epigenetic reprogramming for longevity](https://longevity.openclinics.ru/blog/life-biosciences/)
**Type**: reference
**Relevance**: tertiary
**Category**: reference
**Relationship Description**: Competitor information (Life Biosciences)
**Publisher**: Longevity Open Clinics
**Description**: Information about competitor Life Biosciences and their approach to epigenetic reprogramming

### [Epigenetic aging and cognitive function](https://planet-today.ru/novosti/nauka/item/160425-novoe-issledovanie-svyazyvaet-epigeneticheskoe-starenie-s-kognitivnym-funktsionirovaniem)
**Type**: news_article
**Relevance**: tertiary
**Category**: reference
**Relationship Description**: Article on epigenetic aging and cognitive function (context)
**Publisher**: Planet Today
**Description**: Article linking epigenetic aging with cognitive function, providing context for NewLimit's work

### [January // February 2024 Progress Update](https://blog.newlimit.com/p/january-february-2024-progress-update)
**Type**: blog_post
**Relevance**: secondary
**Category**: source
**Relationship Description**: Company progress update blog post (March 2024)
**Publisher**: NewLimit
**Publication Date**: 2024-03-01
**Description**: Progress update on research and development activities

### [NewLimit Science](https://www.newlimit.com/science)
**Type**: website
**Relevance**: primary
**Category**: source
**Relationship Description**: Scientific approach and technology overview
**Publisher**: NewLimit
**Description**: Scientific approach and technology overview

### [Partial reprogramming for cellular rejuvenation](https://www.nature.com/articles/s41587-022-01434-8)
**Type**: research_publication
**Relevance**: secondary
**Category**: reference
**Relationship Description**: Scientific publication on partial reprogramming (context)
**Publisher**: Nature Biotechnology
**Description**: Review article on partial reprogramming approaches for cellular rejuvenation (general scientific context)

### [May // June 2024 Update](https://blog.newlimit.com/p/may-june-2024-update)
**Type**: blog_post
**Relevance**: secondary
**Category**: source
**Relationship Description**: Company progress update blog post (July 2024)
**Publisher**: NewLimit
**Publication Date**: 2024-07-01
**Description**: Update on company progress and research activities

### [NewLimit raises $45 million to advance longevity research](https://phemex.com/ru/news/article/newlimit-raises-45-million-to-advance-longevity-research-28470)
**Type**: news_article
**Relevance**: primary
**Category**: publication
**Relationship Description**: News about additional funding and liver function restoration breakthrough
**Publisher**: Phemex
**Publication Date**: 2025-06-01
**Description**: News about additional funding round with technological breakthrough in liver function restoration

## Financials

### funding
**Amount**: $45 million USD
**Amount (Numeric)**: 45000000
**Funding Date**: 2025-10-01
**Source**: Strategic Investors
**Funding Type**: Strategic Investment
**Description**: Strategic investment round
**Note**: Strategic investment round
**Details**:
```yaml
year: 2025
investors:
  - Eli Lilly
  - Duke University
  - S32
valuation: $1.62 billion
```

### funding
**Amount**: $130 million USD
**Amount (Numeric)**: 130000000
**Funding Date**: 2025-05-01
**Source**: Venture Capital
**Funding Type**: Series B
**Description**: Series B funding round led by Kleiner Perkins
**Details**:
```yaml
year: 2025
investors:
  - Kleiner Perkins (lead)
  - Nat Friedman
  - Daniel Gross
  - Khosla Ventures
  - Founders Fund
  - Dimension Capital
  - Elad Gil
  - Garry Tan
  - Patrick Collison
valuation: $810 million
lead_investor: Kleiner Perkins
```

### funding
**Amount**: $40 million USD
**Amount (Numeric)**: 40000000
**Funding Date**: 2023-05-01
**Source**: Venture Capital
**Funding Type**: Series A
**Description**: Series A funding round
**Details**:
```yaml
year: 2023
investors:
  - Dimension
  - Founders Fund
  - Kleiner Perkins
  - Eric Schmidt
  - Elad Gil
  - Garry Tan
  - Fred Ehrsam
```

### funding
**Amount**: $110 million USD
**Amount (Numeric)**: 110000000
**Funding Date**: 2021-12-01
**Source**: Founders
**Funding Type**: Seed
**Description**: Seed funding round from founders
**Note**: Initial funding from founders
**Details**:
```yaml
year: 2021
investors:
  - Founders (Brian Armstrong, Blake Byers)
```

## Events

### Company Launch
**Date**: 2021-01-01
**Type**: company_founded
**Description**: NewLimit founded by Brian Armstrong (Coinbase CEO), Blake Byers, and Jacob Kimmel to develop epigenetic reprogramming therapies
**Details**:
```yaml
founders:
  - Brian Armstrong
  - Blake Byers
  - Jacob Kimmel
```

### Seed Funding
**Date**: 2021-12-01
**Type**: funding
**Description**: Raised $110 million in seed funding from founders
**Details**:
```yaml
amount: $110 million
investors:
  - Founders (Brian Armstrong, Blake Byers)
```

### Series A Funding
**Date**: 2023-05-01
**Type**: funding
**Description**: Raised $40 million Series A round led by Dimension, Founders Fund, and Kleiner Perkins, with participation from Eric Schmidt, Elad Gil, Garry Tan, and Fred Ehrsam
**Details**:
```yaml
amount: $40 million
investors:
  - Dimension
  - Founders Fund
  - Kleiner Perkins
  - Eric Schmidt
  - Elad Gil
  - Garry Tan
  - Fred Ehrsam
lead_investors:
  - Dimension
  - Founders Fund
  - Kleiner Perkins
```

### Team Expansion
**Date**: 2024-01-01
**Type**: team_expansion
**Description**: Hired Ron Hause as Head of Computational Sciences (previously SVP and Head of AI at Shape Therapeutics). Expanded team with additional data scientists and research associates
**Details**:
```yaml
key_hire: Ron Hause
position: Head of Computational Sciences
previous_role: SVP and Head of AI at Shape Therapeutics
```

### Preclinical Milestone
**Date**: 2024-12-01
**Type**: milestone
**Description**: Completed first studies in humanized liver models showing successful restoration of youthful functions in aged hepatocytes
**Details**:
```yaml
study: Humanized liver model studies
results: Successful restoration of youthful functions in aged hepatocytes
milestone_type: Preclinical completion
```

### Series B Funding
**Date**: 2025-05-01
**Type**: funding
**Description**: Raised $130 million Series B round led by Kleiner Perkins, valuing the company at $810 million. Investors included Nat Friedman, Daniel Gross, Khosla Ventures, Founders Fund, Dimension Capital, Elad Gil, Garry Tan, and Patrick Collison
**Details**:
```yaml
amount: $130 million
investors:
  - Kleiner Perkins
  - Nat Friedman
  - Daniel Gross
  - Khosla Ventures
  - Founders Fund
  - Dimension Capital
  - Elad Gil
  - Garry Tan
  - Patrick Collison
valuation: $810 million
lead_investor: Kleiner Perkins
```

### Strategic Investment
**Date**: 2025-10-01
**Type**: funding
**Description**: Raised $45 million strategic investment from Eli Lilly, Duke University, and S32, valuing the company at $1.62 billion
**Details**:
```yaml
amount: $45 million
investors:
  - Eli Lilly
  - Duke University
  - S32
valuation: $1.62 billion
```

## Partnerships

### strategic
**Date**: 2025-10-01
**Description**: Eli Lilly participated in $45 million strategic investment round, indicating potential pharmaceutical partnership
**Partner Organizations**:
- Eli Lilly (partner)
  - Strategic pharmaceutical partner
**Details**:
```yaml
type: Strategic Investment
partner: Eli Lilly
investment_amount: $45 million
```

### strategic
**Date**: 2025-10-01
**Description**: Duke University participated in $45 million strategic investment round, indicating potential research collaboration
**Partner Organizations**:
- Duke University (partner)
  - Strategic investor and research collaborator
**Details**:
```yaml
type: Strategic Investment and Collaboration
partner: Duke University
investment_amount: $45 million
```
